It is reported to have similar desirable and unwanted effects to ketamine, although some users have reported that the unwanted effects last longer than for ketamine. Little is known about the potential toxicity of methoxetamine, but people have been hospitalized in the US and UK after using it recreationally. Acute reversible cerebellar toxicity has been documented in three cases of hospital admission due to methoxetamine overdose, lasting for between one and four days after exposure.
Methoxetamine has been marketed as "bladder friendly", referencing the bladder damage associated with chronic ketamine use, but the reasoning behind this seems to have been based purely on the increased potency of methoxetamine compared to ketamine and further scientific research is required to determine whether this is actually the case. From the limited information available based on user reports on internet discussion forums, toxicologists have stated it has "potential to be associated with significant acute harm/toxicity if used as a recreational drug."
It is thought that methoxetamine may be an effective, fast-acting antidepressant like other NMDA antagonists. Its activity at other receptors may contribute to this.
Theresa May commented in her reply to the ACMD that "the next step in this process is for the ACMD to undertake a full assessment of methoxetamine for consideration for its permanent control under the 1971 Act." She goes on to say that she hopes the ACMD will do this as a part of the review of ketamine, "including its analogues" and that this review will be completed "within the 12 months from the making of the current order".
On October 18th 2012 the ACMD released a report about MXE, saying that the "harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act (1971)", despite the fact that the act does not classify drugs based on harm. The report went on to suggest that all analogues of MXE should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexamines.
MXE ceased to be covered by the temporary prohibition on 26 February 2013, when it became classified as a Class B drug. 
MXE became classified as a narcotic in Sweden in late February 2012 .
Mixmag reported in January 2012, that people in the dance music and clubbing community have given methoxetamine the slang name 'roflcoptr'.Vice commented that it was likely that the phrase will only be used by "the same politicians, parents and journalists" who called mephedrone 'meow meow'. After being called mexxy in UK Home Office press releases, the media adopted the name.
A literature review was published in March 2012 which looked at scientific literature and information on the web. It concluded that "the online availability of information on novel psychoactive drugs, such as methoxetamine, may constitute a pressing public health challenge. Better international collaboration levels and novel forms of intervention are necessary to tackle this fast-growing phenomenon."
A forensic standard of Methoxetamine is available, and the compound has been posted on the Forendex website of potential drugs of abuse.
^Kjellgren, A.; Jonsson, K. (2013). "Methoxetamine (MXE) – A Phenomenological Study of Experiences Induced by a "Legal High" from the Internet". Journal of Psychoactive Drugs45 (3): 276. doi:10.1080/02791072.2013.803647.
^ abWood, D. M.; Davies, S.; Puchnarewicz, M.; Johnston, A.; Dargan, P. I. (2011). "Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine". European Journal of Clinical Pharmacology68 (5): 853–856. doi:10.1007/s00228-011-1199-9. PMID22205276.edit
^ abShields, J. E.; Dargan, P. I.; Wood, D. M.; Puchnarewicz, M.; Davies, S.; Waring, W. S. (2012). "Methoxetamine associated reversible cerebellar toxicity: Three cases with analytical confirmation". Clinical Toxicology50 (5): 438–440. doi:10.3109/15563650.2012.683437. PMID22578175.edit
^Corazza, O. et al. (2012). "Phenomenon of New Drugs on the Internet: The Case of Ketamine Derivative Methoxetamine". Human Psychopharmacology: Clinical and Experimental27 (2): 145–149. doi:10.1002/hup.1242. PMID22389078.edit